Researchers have identified a biological marker linked to schizophrenia that could eventually lead to a new type of treatment, especially for symptoms that current medications often fail to improve.U.S. scientists found unusually low levels of a brain protein called CACNA2D1 in people with schizophrenia, raising hopes that the discovery could help address the disorder’s cognitive effects, such as disorganized thinking and executive dysfunction.
The finding matters because today’s antipsychotic drugs mainly target hallucinations and delusions, which are among the best-known symptoms of schizophrenia. However, many patients continue to struggle with cognitive problems that affect daily functioning, independence, and social integration even when psychotic symptoms are partly controlled. These deficits can keep many people with schizophrenia from fully participating in society, making them one of the most difficult parts of the illness to treat.
The research was led by Peter Penzes of Northwestern University Feinberg School of Medicine in Chicago. The team analyzed cerebrospinal fluid samples from more than 100 people, including both individuals with schizophrenia and healthy participants. They found that those with schizophrenia had significantly lower levels of CACNA2D1 than people without the condition. The researchers believe this shortage may contribute to overstimulation in the brain’s electrical networks, which in turn may play a role in the disorder’s cognitive symptoms.
To test whether restoring this protein could help, the scientists created a synthetic version of CACNA2D1 and used it in a mouse model of genetic schizophrenia. Seemingly, a single injection into the animals’ brains corrected abnormal brain circuit activity and improved behaviors associated with the disorder. Just as important, the treatment reportedly did this without causing side effects such as sedation or reduced movement, which are common problems with many psychiatric medications. These early findings suggest the protein may not just be a marker of disease, but also a possible treatment target.
The study, published in the journal Neuron, points toward what researchers described as a combined biomarker-and-therapy strategy. In other words, CACNA2D1 might help doctors identify which patients have a particular biological pattern linked to cognitive dysfunction, while also serving as the basis for a more personalized treatment approach. The researchers see this as a potentially novel path forward in schizophrenia care, one that could move beyond simply suppressing psychotic symptoms and instead focus on restoring brain function more directly.
Still, the work remains at an early stage. The results in humans so far come from measuring protein levels in cerebrospinal fluid, while the treatment results were observed in mice, not in patients. The next step would be to determine which human patients are most likely to respond and then treat them accordingly. That means more research will be needed before any therapy based on this discovery could be tested broadly or turned into a real clinical treatment.
Even with those limits, the discovery stands out because it addresses one of the biggest unmet needs in schizophrenia treatment. If future studies confirm the role of CACNA2D1 and show that replacing or boosting it can safely help people, this line of research could mark an important step toward more precise and more effective schizophrenia care.
